Suchergebnisse - "Ray, Kausik K"

PubPharm (36)

1

Estimating potential cardiovascular health benefits of improved population level control of LDL cholesterol through a twice-yearly siRNA-based approach : A simulation study of a health-system level intervention

enthalten in: Atherosclerosis | 2024

von Ray, K. | Gunn, L. | Conde, L. | +8

2

Reply : Evaluation of the Inclisiran Safety in High-Risk Populations

enthalten in: Journal of the American College of Cardiology | 2024

von Wright, R. | Leiter, L. | Lesogor, A. | +1

3

Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials

enthalten in: Journal of the American College of Cardiology | 2023

von Wright, R. | Koenig, W. | Landmesser, U. | +8

CommentIn: J Am Coll Cardiol. 2023 Dec 12;82(24):2262-2264. - PMID 38057067

4

Inclisiran in patients with prior myocardial infarction : A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials

enthalten in: Atherosclerosis | 2023

von Landmesser, U. | Koenig, W. | Leiter, L. | +6

5

Inclisiran and cardiovascular events : a comprehensive review of efficacy, safety, and future perspectives

enthalten in: Current opinion in cardiology | 2023

von Mohamed, A. | Ray, K.

6

Novel and future lipid-modulating therapies for the prevention of cardiovascular disease

enthalten in: Nature reviews. Cardiology | 2023

von Brandts, J. | Ray, K.

7

Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3) : results from the 4-year open-label extension of the ORION-1 trial

enthalten in: The lancet. Diabetes & endocrinology | 2023

von Ray, K. | Troquay, R. | Visseren, F. | +8

CommentIn: Lancet Diabetes Endocrinol. 2023 Feb;11(2):67-68. - PMID 36620966

8

Effect of inclisiran on lipids in primary prevention : the ORION-11 trial

enthalten in: European heart journal | 2022

von Ray, K. | Kallend, D. | Leiter, L. | +8

CommentIn: Eur Heart J. 2022 Dec 21;43(48):5058-5060. - PMID 36331327

9

Lipid lowering therapy in primary and secondary prevention in Austria : are LDL-C goals achieved? : Results from the DA VINCI study

enthalten in: Wiener klinische Wochenschrift | 2022

von Siostrzonek, P. | Brath, H. | Zweiker, R. | +4

10

EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care : the DA VINCI study

enthalten in: European journal of preventive cardiology | 2021

von Ray, K. | Molemans, B. | Schoonen, W. | +28